Paul Boutros, PhD, MBA, presented “The Prostate Cancer Proteome” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 21, 2023.
How to cite: Boutros, Paul. “The Prostate Cancer Proteome.” September 21, 2023. Accessed Nov 2024. https://grandroundsinurology.com/the-prostate-cancer-proteome/
The Prostate Cancer Proteome – Summary
Paul Boutros, PhD, MBA, gives a talk on the under-explored prostate cancer proteome. Dr. Boutros discusses proteomics by delving into five reasons why they are a useful tool. His talk focuses on these reasons and he goes into detail about each one. They include the fact that proteins are the actual function units of the central dogma, they are far more diverse than RNA, they have not been looked at in much detail yet, they are abundant in urine and they have immense dynamic range. His talk then goes on to cover what tissue proteomics look like, how the proteome relates to other things we care about such as MRI visibility and urinary proteomics. He ends the talk by going over some of the caveats and reasons that proteomics might not work. Overall proteomics are incredibly complex and few have the skills to properly analyze, but it remains a major opportunity to move forward in the field.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Paul C. Boutros, MD, PhD, is a Professor of Human Genetics and Urology at the University of California, Los Angeles. Through UCLA Health, he also runs the Dr. Paul Boutros Lab on Cancer Data Sciences. He earned a BSc degree in Chemistry from the University of Waterloo in Ontario before pursuing a PhD in Medical Biophysics at the Ontario Cancer Institute of the University of Toronto. He also earned his MBA from the Rothman School of Management of the University of Toronto. After receiving his PhD, Dr. Boutros pursued an independent research career as a Fellow and then as a Principal Investigator at the Ontario Institute for Cancer Research. He also served as an Assistant Professor in the Departments of Pharmacology & Toxicology and Medical Biophysics at the University of Toronto. He relocated to UCLA in 2018.
Dr. Boutros’ research focuses on personalizing therapy for cancer by developing novel statistical methodologies. His Cancer Data Sciences Lab uses computational techniques to analyze large data sets to create diagnostics to personalize cancer therapy. He largely focuses on prostate cancer, but his lab is increasingly applying the same computational techniques to other cancers, including kidney and bladder cancers.
Dr. Boutros has received numerous awards and accolades. He is the recipient of the Terry Fox New Investigator Award, a University of Waterloo Young Alumni Award, the Early Career Graduate Student Teaching Award, and the Dorval Prize of the Canadian Cancer Society. He has also been recognized as a Prostate Cancer Canada Rising Star in Prostate Cancer Research.
